Hmpl-004    (DrugBank: -)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
96クローン病1
97潰瘍性大腸炎15

96. クローン病 [臨床試験数:2,209,薬物数:1,276(DrugBank:240),標的遺伝子数:166,標的パスウェイ数:210
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,209 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00655733
(ClinicalTrials.gov)
April 20066/4/2008Phase II Study of HMPL-004 in Subjects With Crohn's DiseaseDouble-blind, Randomized, Multicenter, Placebo-controlled Phase II Study of Efficacy and Safety of HMPL-004 in Subjects With Active Moderate Crohn's DiseaseCrohn's DiseaseDrug: HMPL-004;Drug: PlaceboHutchison Medipharma LimitedNULLCompleted18 YearsN/AAll101Phase 2United States

97. 潰瘍性大腸炎 [臨床試験数:2,269,薬物数:1,331(DrugBank:241),標的遺伝子数:114,標的パスウェイ数:181
Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
15 / 2,269 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2013-003060-31-BG
(EUCTR)
18/06/201410/04/2014A Placebo Controlled Trial of HMPL-004 in Subjects with Mild to Moderate Active Ulcerative ColitisA Phase III Double Blind, Multi-Center Placebo Controlled Maintenance Trial of HMPL-004 in Subjects with Mild to Moderate Ulcerative Colitis with Clinical Remission or Response from Induction Therapy. (NATRUL-4) Ulcerative Colitis (UC)
MedDRA version: 17.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA
Other descriptive name: AND (Andrographolide)
Other descriptive name: NAND (Neoandrographolide)
Other descriptive name: DAND (14-Deoxyandrographolide)
Other descriptive name: DDAND (14-deoxy-11,12-didehydroandrographolide)
Other descriptive name: CLA (Chlorogenic acid)
Other descriptive name: AODG (Apigenin-7-O-glucuronide)
Product Code: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA
Other descriptive name: AND (Andrographolide)
Other descriptive name: NAND (Neoandrographolide)
Other descriptive name: DAND (14-Deoxyandrographolide)
Other descriptive name: DDAND (14-deoxy-11,12-didehydroandrographolide)
Other descriptive name: CLA (Chlorogenic acid)
Other descriptive name: AODG (Apigenin-7-O-glucuronide)
Nutrition Science Partners LimitedNULLNot RecruitingFemale: yes
Male: yes
460Phase 3United States;Hungary;Czech Republic;Poland;Ukraine;Lithuania;Bulgaria;Latvia
2EUCTR2013-003060-31-PL
(EUCTR)
11/06/201419/03/2014A Placebo Controlled Trial of HMPL-004 in Subjects with Mild to Moderate Active Ulcerative ColitisA Phase III Double Blind, Multi-Center Placebo Controlled Maintenance Trial of HMPL-004 in Subjects with Mild to Moderate Ulcerative Colitis with Clinical Remission or Response from Induction Therapy. (NATRUL-4) Ulcerative Colitis (UC)
MedDRA version: 16.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA
Other descriptive name: AND (Andrographolide)
Other descriptive name: NAND (Neoandrographolide)
Other descriptive name: DAND (14-Deoxyandrographolide)
Other descriptive name: DDAND (14-deoxy-11,12-didehydroandrographolide)
Other descriptive name: CLA (Chlorogenic acid)
Other descriptive name: AODG (Apigenin-7-O-glucuronide)
Product Code: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA
Other descriptive name: AND (Andrographolide)
Other descriptive name: NAND (Neoandrographolide)
Other descriptive name: DAND (14-Deoxyandrographolide)
Other descriptive name: DDAND (14-deoxy-11,12-didehydroandrographolide)
Other descriptive name: CLA (Chlorogenic acid)
Other descriptive name: AODG (Apigenin-7-O-glucuronide)
Nutrition Science Partners LimitedNULLNot RecruitingFemale: yes
Male: yes
460Phase 3United States;Hungary;Czech Republic;Poland;Ukraine;Lithuania;Bulgaria;Latvia
3EUCTR2013-003060-31-CZ
(EUCTR)
10/04/201404/02/2014A Placebo Controlled Trial of HMPL-004 in Subjects with Mild to Moderate Active Ulcerative ColitisA Phase III Double Blind, Multi-Center Placebo Controlled Maintenance Trial of HMPL-004 in Subjects with Mild to Moderate Ulcerative Colitis with Clinical Remission or Response from Induction Therapy.(NATRUL-4) Ulcerative Colitis (UC)
MedDRA version: 16.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA
Other descriptive name: AND (Andrographolide)
Other descriptive name: NAND (Neoandrographolide)
Other descriptive name: DAND (14-Deoxyandrographolide)
Other descriptive name: DDAND (14-deoxy-11,12-didehydroandrographolide)
Other descriptive name: CLA (Chlorogenic acid)
Other descriptive name: AODG (Apigenin-7-O-glucuronide)
Product Code: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA
Other descriptive name: AND (Andrographolide)
Other descriptive name: NAND (Neoandrographolide)
Other descriptive name: DAND (14-Deoxyandrographolide)
Other descriptive name: DDAND (14-deoxy-11,12-didehydroandrographolide)
Other descriptive name: CLA (Chlorogenic acid)
Other descriptive name: AODG (Apigenin-7-O-glucuronide)
Nutrition Science Partners LimitedNULLNot RecruitingFemale: yes
Male: yes
460Phase 3United States;Hungary;Czech Republic;Poland;Ukraine;Lithuania;Bulgaria;Latvia
4EUCTR2013-003060-31-HU
(EUCTR)
02/04/201431/01/2014A Placebo Controlled Trial of HMPL-004 in Subjects with Mild to Moderate Active Ulcerative ColitisA Phase III Double Blind, Multi-Center Placebo Controlled Maintenance Trial of HMPL-004 in Subjects with Mild to Moderate Ulcerative Colitis with Clinical Remission or Response from Induction Therapy. (NATRUL-4) Ulcerative Colitis (UC)
MedDRA version: 17.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA
Other descriptive name: AND (Andrographolide)
Other descriptive name: NAND (Neoandrographolide)
Other descriptive name: DAND (14-Deoxyandrographolide)
Other descriptive name: DDAND (14-deoxy-11,12-didehydroandrographolide)
Other descriptive name: CLA (Chlorogenic acid)
Other descriptive name: AODG (Apigenin-7-O-glucuronide)
Product Code: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA
Other descriptive name: AND (Andrographolide)
Other descriptive name: NAND (Neoandrographolide)
Other descriptive name: DAND (14-Deoxyandrographolide)
Other descriptive name: DDAND (14-deoxy-11,12-didehydroandrographolide)
Other descriptive name: CLA (Chlorogenic acid)
Other descriptive name: AODG (Apigenin-7-O-glucuronide)
Nutrition Science Partners LimitedNULLNot RecruitingFemale: yes
Male: yes
460Phase 3United States;Czech Republic;Hungary;Poland;Ukraine;Lithuania;Bulgaria;Latvia
5EUCTR2013-003060-31-LV
(EUCTR)
17/02/201416/12/2013A Placebo Controlled Trial of HMPL-004 in Subjects with Mild to Moderate Active Ulcerative ColitisA Phase III Double Blind, Multi-Center Placebo Controlled Maintenance Trial of HMPL-004 in Subjects with Mild to Moderate Ulcerative Colitis with Clinical Remission or Response from Induction Therapy. (NATRUL-4) Ulcerative Colitis (UC)
MedDRA version: 17.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA
Other descriptive name: AND (Andrographolide)
Other descriptive name: NAND (Neoandrographolide)
Other descriptive name: DAND (14-Deoxyandrographolide)
Other descriptive name: DDAND (14-deoxy-11,12-didehydroandrographolide)
Other descriptive name: CLA (Chlorogenic acid)
Other descriptive name: AODG (Apigenin-7-O-glucuronide)
Product Code: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA
Other descriptive name: AND (Andrographolide)
Other descriptive name: NAND (Neoandrographolide)
Other descriptive name: DAND (14-Deoxyandrographolide)
Other descriptive name: DDAND (14-deoxy-11,12-didehydroandrographolide)
Other descriptive name: CLA (Chlorogenic acid)
Other descriptive name: AODG (Apigenin-7-O-glucuronide)
Nutrition Science Partners LimitedNULLNot RecruitingFemale: yes
Male: yes
460Phase 3United States;Hungary;Czech Republic;Poland;Ukraine;Lithuania;Bulgaria;Latvia
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2013-003060-31-LT
(EUCTR)
11/02/201430/12/2013A Placebo Controlled Trial of HMPL-004 in Subjects with Mild to Moderate Active Ulcerative ColitisA Phase III Double Blind, Multi-Center Placebo Controlled Maintenance Trial of HMPL-004 in Subjects with Mild to Moderate Ulcerative Colitis with Clinical Remission or Response from Induction Therapy. (NATRUL-4) Ulcerative Colitis (UC)
MedDRA version: 16.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA
Other descriptive name: AND (Andrographolide)
Other descriptive name: NAND (Neoandrographolide)
Other descriptive name: DAND (14-Deoxyandrographolide)
Other descriptive name: DDAND (14-deoxy-11,12-didehydroandrographolide)
Other descriptive name: CLA (Chlorogenic acid)
Other descriptive name: AODG (Apigenin-7-O-glucuronide)
Product Code: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA
Other descriptive name: AND (Andrographolide)
Other descriptive name: NAND (Neoandrographolide)
Other descriptive name: DAND (14-Deoxyandrographolide)
Other descriptive name: DDAND (14-deoxy-11,12-didehydroandrographolide)
Other descriptive name: CLA (Chlorogenic acid)
Other descriptive name: AODG (Apigenin-7-O-glucuronide)
Nutrition Science Partners LimitedNULLNot RecruitingFemale: yes
Male: yes
460Phase 3United States;Hungary;Czech Republic;Poland;Ukraine;Lithuania;Bulgaria;Latvia
7EUCTR2013-002116-27-BG
(EUCTR)
19/12/201316/10/2013A Placebo Controlled Trial of HMPL-004 in Subjects with Mild to Moderate Active Ulcerative ColitisA Phase III, Randomized, Multi-Centre, Double-Blind,Placebo-Controlled Trial of HMPL-004 in Subjects with Mild to Moderate Active Ulcerative Colitis (NATRUL-3) Ulcerative Colitis (UC)
MedDRA version: 17.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA
Other descriptive name: AND (Andrographolide)
Other descriptive name: NAND (Neoandrographolide)
Other descriptive name: DAND (14-Deoxyandrographolide)
Other descriptive name: DDAND (14-deoxy-11,12-didehydroandrographolide)
Other descriptive name: CLA (Chlorogenic acid)
Other descriptive name: AODG (Apigenin-7-O-glucuronide)
Product Code: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA
Other descriptive name: AND (Andrographolide)
Other descriptive name: NAND (Neoandrographolide)
Other descriptive name: DAND (14-Deoxyandrographolide)
Other descriptive name: DDAND (14-deoxy-11,12-didehydroandrographolide)
Other descriptive name: CLA (Chlorogenic acid)
Other descriptive name: AODG (Apigenin-7-O-glucuronide)
Nutrition Science Partners LimitedNULLNot RecruitingFemale: yes
Male: yes
420Phase 3United States;Hungary;Czech Republic;Poland;Ukraine;Lithuania;Bulgaria;Latvia
8EUCTR2013-002116-27-LT
(EUCTR)
14/11/201306/08/2013A Placebo Controlled Trial of HMPL-004 in Subjects with Mild to Moderate Active Ulcerative ColitisA Phase III, Randomized, Multi-Centre, Double-Blind,Placebo-Controlled Trial of HMPL-004 in Subjects with Mild to Moderate Active Ulcerative Colitis (NATRUL-3) Ulcerative Colitis (UC)
MedDRA version: 16.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA
Other descriptive name: AND (Andrographolide)
Other descriptive name: NAND (Neoandrographolide)
Other descriptive name: DAND (14-Deoxyandrographolide)
Other descriptive name: DDAND (14-deoxy-11,12-didehydroandrographolide)
Other descriptive name: CLA (Chlorogenic acid)
Other descriptive name: AODG (Apigenin-7-O-glucuronide)
Product Code: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA
Other descriptive name: AND (Andrographolide)
Other descriptive name: NAND (Neoandrographolide)
Other descriptive name: DAND (14-Deoxyandrographolide)
Other descriptive name: DDAND (14-deoxy-11,12-didehydroandrographolide)
Other descriptive name: CLA (Chlorogenic acid)
Other descriptive name: AODG (Apigenin-7-O-glucuronide)
Nutrition Science Partners LimitedNULLNot RecruitingFemale: yes
Male: yes
420Phase 3United States;Hungary;Czech Republic;Poland;Ukraine;Lithuania;Bulgaria;Latvia;Korea, Republic of
9EUCTR2013-002116-27-LV
(EUCTR)
28/10/201326/06/2013A Placebo Controlled Trial of HMPL-004 in Patients with Mild to Moderate Active Ulcerative ColitisA Phase III, Randomized, Multi-Centre, Double-Blind,Placebo-Controlled Trial of HMPL-004 in Patients with Mild to Moderate Active Ulcerative Colitis (NATRUL-3) Ulcerative Colitis (UC)
MedDRA version: 17.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA
Other descriptive name: AND (Andrographolide)
Other descriptive name: NAND (Neoandrographolide)
Other descriptive name: DAND (14-Deoxyandrographolide)
Other descriptive name: DDAND (14-deoxy-11,12-didehydroandrographolide)
Other descriptive name: CLA (Chlorogenic acid)
Other descriptive name: AODG (Apigenin-7-O-glucuronide)
Nutrition Science Partners LimitedNULLNot RecruitingFemale: yes
Male: yes
420Phase 3United States;Hungary;Czech Republic;Poland;Ukraine;Lithuania;Bulgaria;Latvia;Korea, Republic of
10EUCTR2013-002116-27-HU
(EUCTR)
24/10/201324/07/2013A Placebo Controlled Trial of HMPL-004 in Patients with Mild to Moderate Active Ulcerative ColitisA Phase III, Randomized, Multi-Centre, Double-Blind,Placebo-Controlled Trial of HMPL-004 in Patients with Mild to Moderate Active Ulcerative Colitis (NATRUL-3) Ulcerative Colitis (UC)
MedDRA version: 17.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA
Other descriptive name: AND (Andrographolide)
Other descriptive name: NAND (Neoandrographolide)
Other descriptive name: DAND (14-Deoxyandrographolide)
Other descriptive name: DDAND (14-deoxy-11,12-didehydroandrographolide)
Other descriptive name: CLA (Chlorogenic acid)
Other descriptive name: AODG (Apigenin-7-O-glucuronide)
Nutrition Science Partners LimitedNULLNot RecruitingFemale: yes
Male: yes
420Phase 3United States;Czech Republic;Hungary;Poland;Ukraine;Lithuania;Bulgaria;Latvia;Korea, Republic of
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2013-002116-27-CZ
(EUCTR)
09/10/201308/08/2013A Placebo Controlled Trial of HMPL-004 in Subjects with Mild to Moderate Active Ulcerative ColitisA Phase III, Randomized, Multi-Centre, Double-Blind,Placebo-Controlled Trial of HMPL-004 in Subjects with Mild to Moderate Active Ulcerative Colitis (NATRUL-3) Ulcerative Colitis (UC)
MedDRA version: 16.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA
Other descriptive name: AND (Andrographolide)
Other descriptive name: NAND (Neoandrographolide)
Other descriptive name: DAND (14-Deoxyandrographolide)
Other descriptive name: DDAND (14-deoxy-11,12-didehydroandrographolide)
Other descriptive name: CLA (Chlorogenic acid)
Other descriptive name: AODG (Apigenin-7-O-glucuronide)
Product Code: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA
Other descriptive name: AND (Andrographolide)
Other descriptive name: NAND (Neoandrographolide)
Other descriptive name: DAND (14-Deoxyandrographolide)
Other descriptive name: DDAND (14-deoxy-11,12-didehydroandrographolide)
Other descriptive name: CLA (Chlorogenic acid)
Other descriptive name: AODG (Apigenin-7-O-glucuronide)
Nutrition Science Partners LimitedNULLNot RecruitingFemale: yes
Male: yes
420Phase 3United States;Hungary;Czech Republic;Poland;Ukraine;Lithuania;Bulgaria;Latvia;Korea, Republic of
12NCT01882764
(ClinicalTrials.gov)
June 201317/6/2013HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative ColitisA Phase III Double Blind, Multi-Center Placebo Controlled Maintenance Trial of HMPL-004 in Subjects With Mild to Moderate Ulcerative Colitis With Clinical Remission or Response From Induction Therapy. (NATRUL-4)Ulcerative ColitisDrug: HMPL-004;Drug: PlaceboHutchison Medipharma LimitedNutrition Science Partners LimitedTerminated18 YearsN/AAll66Phase 3United States
13NCT01805791
(ClinicalTrials.gov)
March 20134/3/2013A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative ColitisA Phase III, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative ColitisUlcerative ColitisDrug: HMPL-004 1800 mg/day;Drug: Placebo;Drug: HMPL-004 2400 mg/dayHutchison Medipharma LimitedNULLTerminated18 Years75 YearsAll201Phase 3United States
14EUCTR2007-005166-12-DE
(EUCTR)
29/07/200815/01/2008A Phase II, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients with Mild to Moderate Active Ulcerative Colitis with or without MesalamineA Phase II, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients with Mild to Moderate Active Ulcerative Colitis with or without Mesalamine active mild to moderate ulcerative colitis defined as a Mayo clinical score of 4-10 points
MedDRA version: 9.1;Level: LLT;Classification code 10066678;Term: Acute ulcerative colitis
Product Name: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA (ethanol extract)
Product Name: HMPL-004
Other descriptive name: ANDROGRAPHIS PANICULATA (ethanol extract)
Hutchison MediPharma Enterprises LimitedNULLNot RecruitingFemale: yes
Male: yes
210Phase 2Germany
15NCT00659802
(ClinicalTrials.gov)
February 7, 20088/4/2008Phase II Study of HMPL-004 in Patients With Ulcerative ColitisA Phase II, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis With or Without MesalamineUlcerative ColitisDrug: HMPL-004 low dose;Drug: Placebo;Drug: HMPL-004 high doseHutchison Medipharma LimitedNULLCompleted18 YearsN/AAll224Phase 2United States